Several smallcap stocks have crossed their 100-day Simple Moving Average (SMA), offering potential growth opportunities. Notable performers...

Four consistent performers in the Indian stock market have been identified through a screener search, each having delivered over 25% annual...

Gujarat Themis Biosyn, an India-based pharma firm, has announced a 1:5 stock split and a dividend of Rs 1 for the financial year ended Marc...

Vesuvius India, Repro India, DJ Mediaprint & Logi, Themis Medicare and Sotac Pharmaceutical, hit their fresh 52-week highs at 10:35AM.

Gujarat Themis Biosyn Ltd. key Products/Revenue Segments include Pharmaceuticals, Scrap for the year ending 31-Mar-2022.

Shares of Chandra Prabhu International (Rs 10 to Rs 2) will turn ex-split. A meeting of the board of directors of Indo Cotspin is scheduled...

Wednesday is the record date for dividend by Data Patterns (India) (Rs 3.5 per share), Ion Exchange (Rs 10 per share), RSWM (Rs 25 per shar...

Themis had launched inosine pranobex under brand name Viralex in June this year. Despite the drug not figuring in the government's Covid tr...

Mumbai-based pharmaceutical company Themis Medicare’s anti-viral drug Viralex has received Drugs Controller General of India’s (DCGI) appro...

It also announced a partnership with privately-held Ridgeback Biotherapeutics to develop an experimental oral antiviral drug against COVID-...

Bitcoin's meteoric rise is attracting a ton of attention. Is it ready for the mainstream?

The New Jersey-based specialty pharmaceutical firm Navakar has expertise in commercialising pharma products in the US as well as global mar...

Novartis’ Voveran 1ml and Themis' Aquadol have competed with Troikaa’s own injection to manage pain, Dynapar AQ, since their launch in 2013.

Mumbai Angels, Kae Capital, Rehan Yar Khan’s Orios Ventures, Indian Angel Network and Ankur Capital will be participating in the exercise.

Mauritius-based private equity fund New York Life Investment Management Jacob Ballas India Fund has acquired a “minority” stake in Mumbai-b...

Aventis Pharma and Themis Laboratories have signed a technology transfer agreement for fixed-dose combinations comprising glibenclamide (Da...